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Abstract
Background: Dupuytren's contracture or disease (DD) is a fibro-proliferative disease of the hand
that results in finger flexion contractures. Increased cellular β-catenin levels have been identified as
characteristic of this disease. As Wnts are the most widely recognized upstream regulators of
cellular β-catenin accumulation, we have examined Wnt gene expression in surgical specimens and
in DD-derived primary cell cultures grown in two-dimensional monolayer culture or in three-
dimensional FPCL collagen lattice cultures.
Results: The Wnt expression profile of patient-matched DD and unaffected control palmar fascia
tissue was determined by a variety of complimentary methods; Affymetrix Microarray analysis,
specific Wnt and degenerative primer-based Reverse Transcriptase (RT)-PCR, and Real Time PCR.
Microarray analysis identified 13 Wnts associated with DD and control tissues. Degenerate Wnt
RT-PCR analysis identified Wnts 10b and 11, and to a lesser extent 5a and 9a, as the major Wnt
family members expressed in our patient samples. Competitive RT-PCR analysis identified
significant differences between the levels of expression of Wnts 9a, 10b and 11 in tissue samples
and in primary cell cultures grown as monolayer or in FPCL, where the mRNA levels in tissue >
FPCL cultures > monolayer cultures. Real Time PCR data confirmed the down-regulation of Wnt
11 mRNA in DD while Wnt 10b, the most frequently isolated Wnt in DD and control palmar fascia,
displayed widely variable expression between the methods of analysis.
Conclusion: These data indicate that changes in Wnt expression per se are unlikely to be the cause
of the observed dysregulation of β-catenin expression in DD.
Background
Dupuytren's contracture or disease (DD) is a benign fibro-
proliferative disease of the hand that causes permanent
finger flexion contractures [1,2]. Despite its long medical
history and high prevalence among Caucasians of North-
ern European ancestry, reportedly as high as 30–40% [3],
the underlying genetic etiology of the disease remains
unknown [4]. Numerous risk factors have been reported
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for DD, including alcoholism, trauma, diabetes, smoking,
and epilepsy, but their exact role in the disease is not clear
[5]. Epidemiological studies show an increased total mor-
tality and cancer mortality rates among men with estab-
lished DD [6], suggesting the pathophysiology of this
disease may overlap with that of certain cancers.
β- catenin, the central component of the 'canonical' Wnt
signalling pathway (herein referred to as Wnt/β-catenin)
has been implicated in the pathogenesis of DD [7-9], and
abnormal  β-catenin levels in primary DD cell cultures
have been shown to vary with specific cell culture condi-
tions [8,9]. β-Catenin plays both a structural role, as a cad-
herin-binding protein in cell adhesion junctions [10,11],
and a signalling role, as part of the Wnt/β-catenin path-
way [12]. Wnts are a large family of lipid modified glyco-
proteins [13] that regulate various cellular processes
important to normal embryonic development [14]. Wnts
act as paracrine factors, initiating cell signalling by bind-
ing to Frizzled (Fz) receptors. The Wnt/Fz complex can
then activate one of three distinct signalling pathways that
control either cell fate or differentiation (Wnt/β-cat-
enin)[14], planar cell polarity (PCP)[15], or cell adhesion
(Wnt/Ca+2/PKC)[16,17]. The co-receptor LRP5/6 (lipo-
protein receptor-related proteins 5 or 6) is required for
Wnt/β-catenin pathway signalling [18-20]. Once acti-
vated, the Wnt/Fz/LRP complex triggers a cascade of sig-
nalling events that ultimately lead to the stabilization of a
'cadherin-free' cytoplasmic pool of β-catenin. The cyto-
plasmic accumulation of β-catenin results in its transloca-
tion to the nucleus where it functions as a transcriptional
activator for members of the lymphoid enhancer factor/T-
cell factor (Lef/Tcf) family of DNA binding proteins
[21,22].
The importance of the Wnt/β-catenin signalling is under-
scored by its targeted disruption in human diseases. For
example, several members of the Wnt/β-catenin pathway
are mutated in a variety of human malignancies [23-27].
Normally, in the absence of a 'canonical' Wnt signal or an
activating mutational event, the cytoplasmic 'free' pool of
β-catenin becomes serine/threonine phosphorylated,
ubiquitinated (Ub) and degraded in the proteasome, via
an axin-based 'destruction' complex. Axin with the aid of
APC (adenomatous polyposis coli) binds to β-catenin
[28], which facilitates its phosphorylation [29] via a dual
kinase mechanism involving CKI (casein kinase-1) and
GSK-3β (glycogen synthase kinase-3β) [30-32]. CKI,
which is recruited to the destruction complex by the axin
binding protein diversin [33], phosphorylates β-catenin at
serine 45, an important priming step required by GSK-3β
to mediate β-catenin phosphorylation at threonine 41,
serine 37 and serine 33. This hyper-phosphorylated form
of β-catenin is then recognized by the F-box containing
protein slimb/β-TrCP, a component of the E3 ubiquitin
(Ub) ligase complex, and β-catenin is targeted for degra-
dation via the 26S proteasome [34-38]. Not surprisingly,
the critical serine/threonine residues of β-catenin that are
phosphorylated by GSK-3β are mutational 'hot spots' in
many cancers. We have previously shown that, unlike the
situation in tumors, this region (exon 3) of the β-catenin
gene derived from DD samples does not contain such
mutations [8]. Given the proposed role of Wnt/β-catenin
signalling in DD, in this paper, we set out to examine Wnt
expression in DD.
Utilizing multiple approaches, we demonstrate here that
multiple Wnts are expressed within patient lesions and
control normal palmar fascia (PF) tissue. The pattern of
Wnt expression observed in tissue samples is altered by in
vitro culture method. Comparison of Wnt mRNA levels in
DD and control tissues as well as examination of primary
cultures of DD cells reveal that the level and type of Wnt
expression is highly variable in this fibroproliferative dis-
ease with the only consistent finding being down-regu-
lated Wnt 11 mRNA expression in disease tissue. As Wnt-
11 signalling is independent of β-catenin and no other
Wnt family members display consistent alteration in
expression, this data suggests other, as yet unidentified,
factors are dysregulating β-catenin processing in DD.
Results
Affymetrix microarray analysis
The primary goal of this project was to determine the
expression status of all Wnts expressed in DD and control
palmar fascia (PF). To achieve this, surgically resected DD
and control patient samples were examined using Affyme-
trix Microarray as described in the methods. As shown in
Figure 1, 13 of the 19 Wnts (for a review of Wnt factors:
http://www.stanford.edu/~rnusse/wntgenes/human
wnt.html) were identified as being expressed in DD. Data
indicated that the majority of Wnts detected in both DD
and control were expressed at very similar levels with only
Wnts 5a and 11 displaying any variance in expression
between disease and control tissues.
Wnt expression profiling in vivo and in vitro using Wnt 
specific primers
To confirm the Microarray data and to assess the relative
contribution of each of these 13 Wnts in DD and control
PF, a Wnt expression profiling study was initiated utilizing
Wnt degenerate primer analysis. Prior to commencing
these experiments, however, it was necessary to determine
the optimal samples for analysis. We have previously
reported that β-catenin levels are abnormal in DD tissue
but not in primary cell isolates grown in two-dimensional
monolayer culture, whereas three-dimensional culture of
the same primary cell lines in FPCL can recapitulate
abnormal β-catenin expression [8,9]. The initial experi-
ments involved the isolation of total RNA from surgicallyJournal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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resected patient samples and primary cell cultures grown
either in two-dimensional monolayer culture or in three-
dimensional FPCL culture as described in the methods.
Total RNA samples were then reverse transcribed and the
cDNA templates were amplified by PCR using Wnt degen-
erate oligonucleotide primers (Fig. 2). Clones of the PCR
amplified products were isolated, and the cloned inserts
from purified plasmid DNA digested with a series of diag-
nostic restriction enzymes to identify the corresponding
Wnt subtype as described in the methods. Clones were
categorized based on the Wnt-specific DNA fragment
sizes, and several representative clones from each group
sequenced. The clones isolated from control and disease
PF tissue displayed a similar Wnt expression pattern, with
Wnt 5a, 9a, 10b, and 11 accounting for almost all of the
identifiable disease and control clones detected by this
approach (as shown in Table 1). Two clones representing
Wnts 8b and 9b were also isolated. Comparisons of the in
vivo and in vitro expression levels of the major group of
Wnts (5a, 9a, 10b, and 11) were performed by RT-PCR
using the Wnt-specific oligonucleotide primers as
described in the methods. As shown in Figure 3, three of
the four Wnts (5a, 9a and 11) were readily detectable
within FPCL cultures, while only two Wnts (5a and 11)
were detected in confluent monolayer cultures. Wnt5a
expression levels were relatively high for both monolayer
and FPCL cultures and quite similar to the levels seen in
vivo. However, comparisons between the in vivo and in
vitro expression levels of Wnt 9a, 10b and 11 showed sig-
nificant differences. Specifically, a distinct expression
hierarchy (in vivo > FPCL > confluent monolayer) was
shared by Wnts 9a, 10b and 11. Wnt10b expression was
very low or undetectable in the majority of the FPCL cul-
tures and largely undetectable in the confluent monolayer
cultures.
Based on this data, we concluded that these in vitro cul-
ture conditions do not recapitulate in vivo Wnt expression
and that only RNA isolated directly from surgical speci-
mens would be suitable to obtain an accurate representa-
tion of Wnt expression in DD.
Wnt expression profiling in DD and control palmar fascia 
by reverse transcription and degenerate primer PCR 
analysis
In light of the results from the in vitro and in vivo studies
described above, a comprehensive Wnt expression profil-
ing study was performed on RNA isolated directly from
surgical specimens utilizing reverse transcription and Wnt
degenerate primer PCR analysis. PCR products (~400 bp)
were subcloned into the pCR® 4-TOPO® sequencing vector
and clones were isolated as described in the methods. The
DNA restriction analysis was performed and a representa-
tive subgroup of clones were sequenced to confirm Wnt
identity. In total, 182 clones were isolated and identified
by restriction enzyme analysis to yield a representative
overview of Wnt expression in DD and control palmar fas-
cia. As shown in Table 1, Wnts 5a, 9a, 10b, and 11
accounted for all clonal isolates. Specifically, Wnts 5a, 9a,
10b, and 11 represented 18%, 19%, 14% and 49% of the
control clones (n = 57), and 15%, 2%, 73% and 12% of
the disease clones (n = 125), respectively (total 182).
Real Time PCR of Wnt 10b and Wnt 11 expression in DD 
and control palmar fascia
Wnts 10b and 11 represented the majority of clonal iso-
lates from DD and control tissues and their representation
within each group appeared to correlate with the presence
of disease. To better compare the expression levels of these
Wnts, we performed Real Time PCR of Wnt 10b and Wnt
11 mRNA in surgical samples of DD and normal PF con-
trol using the relative quantitation method. As shown in
Figure 4, both Wnt 10b and Wnt 11 mRNA levels were sig-
nificantly decreased in total RNA derived from DD cord
(Mann-Whitney Test, Wnt 10b P = 0.038, Wnt 11 P =
0.014). The expression levels of Wnt10b did not reflect
the representation in the clones derived from the degener-
ate primer analysis or the Affymetrix Microarray analysis.
Wnt 11 mRNA expression, by comparison, was lower in
DD tissue than control palmar fascia by all of the tech-
niques employed. With the exception of Wnt 11, direct
comparison of the Wnt expression analysis reported here
indicated that the level and type of Wnt expression is not
altered between DD and control PF.
Affymetrix microarray of Wnt expression Figure 1
Affymetrix microarray of Wnt expression. 3 DD and 3 
control samples were analyzed using the Human Genome 
U133 Plus 2.0 Array. The data generated represents the 
expression analysis from all samples. The data was sorted 
and normalized using Genespring software. The control value 
(mean of three samples relative to normalization of control 
#1 and corresponding disease value (mean of three samples) 
is shown beneath each Wnt designation on the X axis. The 
graph displays the mean values of each group ± standard 
deviation.Journal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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Discussion
Wnt expression is altered in a variety of cancers including
prostate and colon carcinoma [39,40], where β-catenin
accumulation and associated gene transcription are
believed to contribute to the tumor growth. As we and
others have previously shown that abnormal cytoplasmic
accumulation of β-catenin is present in DD, we have
hypothesized that β-catenin is a central molecular media-
tor of its pathophysiology [7-9]. As Wnt factors are the
most upstream regulating factors of β-catenin levels, we
have undertaken a comprehensive analysis of Wnt expres-
sion in this disease.
Of the 19 Wnts identified to-date, 13 were detected by
Affymetrix Microarray analysis in both DD and PF control
tissue. Normalized expression analysis indicated that the
majority of Wnts were expressed at equivalent levels in
both disease and control samples with only Wnt 11 and
Wnt 5a displaying any suggestion of altered expression. A
large standard deviation was noted in the control samples
for Wnt 11 (mean 1.29, SD 0.72) and the disease samples
for Wnt5a (mean 2.62, SD 1.05). The Wnt expression of
the control sample derived from a patient undergoing car-
pal tunnel release was not significantly different from the
Wnt expression of the control samples derived from pal-
mar fascia adjacent to disease cord in all cases including
Wnt 11, where it was the sample closest to the mean (data
Table 1: Wnt expression profiling of surgical fascia tissue 
specimens.
Patient Fascia Type Wnt 5a Wnt 9a Wnt 10b Wnt 11
D2 Control 5/37 9/37 3/37 20/37
Pooled Control 4/17 0/17 5/17 8/17
W Control 1/3 2/3 0/3 0/3
D Disease 0/28 1/28 27/28 0/28
D2 Disease 1/4 0/4 2/4 1/4
E Disease 0/16 0/16 16/16 0/16
M Disease 0/9 0/9 9/9 0/9
H2 Disease 0/16 0/16 16/16 0/16
L Disease 0/2 1/2 1/2 0/2
R Disease 2/9 0/9 7/9 0/9
T Disease 5/22 1/22 10/22 6/22
W Disease 11/19 0/19 3/19 8/19
In total, 9 disease, 7 control or normal fascia specimens (2 individual 
+ 5 that were 'pooled' together) and were subjected to RT-PCR 
using degenerate Wnt primers. Four different Wnt species were 
identified; Wnt5a, 9a, 10b and 11 which were isolated from 18%, 
19%, 14% and 49% of the control clones (n = 57), and 15%, 2%, 73% 
and 12% of the disease clones (n = 125), respectively (total 182)
Degenerate primer design Figure 2
Degenerate primer design. Degenerative Wnt primers (designated Upper and Lower Primers) were designed using the 
ClustalW program with the aid of the BioEdit sequence alignment editor. Comparison of the published nucleic acid sequences 
for the 13 human Wnts detected by Affymetrix Microarray revealed two highly conserved regions that were used to design 
degenerate oligonucleotide primers for PCR amplification as shown.Journal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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not shown). As such, none of the variability in Wnt
expression was readily attributable to genetic background.
The primary advantage of the Microarray approach is the
ability to sensitively screen the expression levels of a large
number of mRNA transcripts in a process with low
between-assay variability. This tool is designed to com-
pare samples, in this case DD and control PF, and the rea-
dout is designed so that control readings are normalized
and disease values are reported relative to that normalized
value. Thus, in this study the Microarray analysis yielded
an accurate and comprehensive overview of Wnt expres-
sion in the samples of DD and control PF without indicat-
ing the relative abundance of each Wnt subtype within
each category. While this data indicated that both Wnt 5a
and Wnt 11 expression were potentially altered in DD, it
was unclear what percentage of the total Wnt signalling
potential of the cells was represented by these two tran-
scripts.
To more rigorously determine the relative contributions
of the 13 Wnt transcripts detected, we therefore continued
our analysis by determining the Wnt expression profile
utilizing degenerate primers. Progressive multiple
sequence alignment of the Wnt gene family using Clus-
talW [41] revealed several highly conserved regions that
could be used to design degenerate oligonucleotide prim-
ers as previously described [42], that would be able to
amplify all 13 Wnts identified in the microarray. This
approach has the advantage of being amenable to assess-
ing large numbers of samples with the options of restric-
tion enzyme analysis and/or sequence level identification
of the clonal isolates. Further, as each cDNA is generated
from the total RNA pool, the amplified products would be
predicted to be isolated at a frequency proportional to the
initial abundance of the mRNA transcripts.
Initial Wnt expression profiling experiments were directed
at determining the appropriate sample for analysis. This
was essential, as the central hypothesis of this study was
that alterations in Wnt signalling could be the primary
cause of the altered cellular accumulation of β-catenin evi-
dent by immunohistochemistry of DD tissue. We have
Real time relative quantitation of Wnt 10b and Wnt 11  expression in DD vs Figure 4
Real time relative quantitation of Wnt 10b and Wnt 
11 expression in DD vs. control. Real time relative quan-
titation of PCR amplicons was performed on an ABI Prism 
7700 using the comparative Ct method. UPPER PANELS: 
Determination of relative amplification efficiencies for 
Wnt10b vs. β-actin and Wnt11 vs. β-actin. As shown, target 
and endogenous control gene products amplified with similar 
efficiency. The Δ CT value (CTtarget/CTendogenous control) was 
determined to be 0.1696 and 0.1619 for Wnt 10b/β-actin and 
Wnt 11/β-actin respectively. LOWER PANEL: Real time rela-
tive PCR quantitation for Wnt10b and Wnt11 mRNAs per-
formed on a separate subset of 7 DD and 6 PF control 
samples derived from surgical resection. Triplicate reactions 
of each dilution were performed (50 μl samples) in a 96-well 
plate format using SDS instrumentation (Applied Biosystems) 
for 45 cycles. Target and endogenous control reaction were 
run in separate wells in triplicate at each concentration. Rela-
tive Quantitation of Wnt 10b and Wnt 11 mRNA levels in 
normal palmar fascia (mean Wnt 10b = 20.74 ± 8.81, Wnt 11 
= 40.89 ± 12.86) were significantly (*) different to DD (Wnt 
10b = 4.83 ± 2.21; P = 0.038, Wnt 11 = 7.56 ± 4.50; P = 
0.014, Mann Whitney Test). Data is shown as Mean ± SEM.
Comparison of Wnt expression in RNA derived from tissue,  FPCL and monolayer culture Figure 3
Comparison of Wnt expression in RNA derived from 
tissue, FPCL and monolayer culture. Comparisons of 
the in vivo and in vitro expression levels of Wnts 5a, 9a, 10b, 
and 11 were performed by RT-PCR using the Wnt-specific 
oligonucleotide primers from RNA derived from DD and PF 
control samples. As shown, a distinct expression hierarchy 
(Tissue > FPCL > monolayer) was shared by Wnts 9a, 10b 
and 11 with Wnts 9a and 10b being undetected in monolayer 
culture. Wnt5a expression levels were unaffected by culture 
conditions. In all cases Wnt expression was normalized to 
GAPDH expression and represent the mean value ± stand-
ard deviation.Journal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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previously reported that this accumulation of β-catenin in
DD was not detected by western blotting of primary cell
isolates grown in two-dimensional monolayer culture [8].
Three-dimensional cultures of the same primary cell lines
in Fibroblast Populated Collagen Lattices (FPCL), how-
ever, were able to qualitatively reflect in vivo β-catenin
expression due, at least in part, to the addition of appro-
priate isometric tension [9]. As this study was inherently
quantitative, it was of interest to determine the effect of
isometric tension and three-dimensional FPCL culture on
the level of Wnt expression and to determine how Wnt
expression level in FPCL compared to Wnt expression in
vivo.
The analysis of clones by restriction analysis and sequenc-
ing revealed that Wnts 5a, 9a, 10b, and 11 accounted for
the vast majority of the disease and control-derived clones
that could be identified by this approach. Comparisons of
the in vivo and in vitro expression levels of these Wnts (5a,
9a, 10b, and 11) were performed by RT-PCR using the
Wnt-specific oligonucleotide primers. Three of the four
Wnts (5a, 9a and 11) were readily detectable within FPCL
cultures, while only two Wnts (5a and 11) were detected
in confluent monolayer cultures. Wnt 5a expression levels
were relatively high for both monolayer and FPCL cul-
tures and quite similar to the levels seen in vivo. However,
comparisons between the in vivo and in vitro expression
levels of Wnt 9a, 10b and 11 showed significant differ-
ences. Specifically, a distinct expression hierarchy (in vivo
> FPCL > confluent monolayer) was shared by Wnts 9a,
10b and 11. Wnt10b expression was very low or undetec-
table in the majority of the FPCL cultures and largely
undetectable in the confluent monolayer cultures.
Based on these data, we concluded that these in vitro cul-
ture conditions do not recapitulate in vivo Wnt expression
and that RNA isolated directly from surgical specimens is
required to obtain an accurate representation of Wnt
expression in DD. A comprehensive Wnt expression pro-
file of 182 clones was generated utilizing reverse transcrip-
tion and Wnt degenerate primer PCR analysis. As shown
in Table 1, Wnt 5a was evident in 15% of DD- derived
clones and 18% of control derived clones, indicating that
there was no difference in expression level between these
groups. In contrast, the relative abundance of clones con-
taining Wnts 10b and 11, and to a lesser extent 9b,
sequences varied considerably between DD and controls.
Wnt 11 was evident in 49% of control tissue – derived
clones but only 12% of those derived from disease tissue,
whereas Wnt 10b displayed the opposite trend being
present in only 14% of control-derived clones compared
to 73% of DD-derived clones. Wnt10b is recognized to
primarily signal via the "canonical" pathway leading to
downregulation of GSK-3β activity and cytoplasmic accu-
mulation of β-catenin [43]. Wnt 11, while less well char-
acterized, has been shown to be associated with the "non-
canonical" cell adhesion (Wnt/Ca+2/PKC) pathway [44].
As this data could imply a shift to increased Wnt 10b
expression and decreased Wnt 11 expression in DD, con-
sistent with an increase in signalling through the canoni-
cal pathway, it was essential to independently confirm
these data.
To achieve this, Wnt 10b and Wnt 11 expression were
quantitated by Real Time PCR on an additional subset of
7 DD and 6 PF control samples derived directly from sur-
gical resection. As shown in Figure 4, these results indicate
that Wnt 10b expression was significantly decreased
between disease and control samples. The lack of correla-
tion between Wnt 10b expression in the Affymetrix Micro-
array analysis, which indicated no change between DD
and control samples, the degenerate primer analysis,
which indicated an increased abundance of cDNAs
derived from Wnt 10b mRNA, and the decreased Wnt 10b
mRNA levels revealed by Real Time PCR data, was unex-
pected. These contradictory findings dictate that an exclu-
sion of changes in Wnt 10b mRNA expression in the
pathophysiology of DD cannot be made at this time. Wnt
11 mRNA expression was also variable, however in this
case a consistent decrease in expression between disease
and control samples was evident in all of the analytical
techniques employed. Wnt 11 is reported to signal
through a non-canonical pathway that does not affect β-
catenin accumulation [44,45]. The absence of consistent
changes in the mRNA expression of any other Wnts iden-
tified in DD that could lead to a shift to canonical Wnt sig-
nalling indicates that, accounting for variability between
individual samples, there is no evidence of a consistent
alteration in Wnt mRNA expression in DD that would
alter β-catenin accumulation.
While Wnt expression is unchanged, it should be noted
that these data do not rule out alterations in Wnt signal-
ling in the pathogenesis of this disease. Wnt signalling
efficiency has been shown to be altered in a variety of
tumors secondary to changes in the expression of secreted
Wnt antagonists, such as the Dickkopf family, Wnt inhib-
itory factor-1 and secreted Frizzled-related protein (sFRP)
family [46-48]. Our Affymetrix Microarray data indicated
that there was a consistent reduction in sFRP-1 expression
in the 3 DD samples screened relative to PF control levels
(data not shown). It is possible, therefore, that alterations
in total (rather than individual) Wnt signalling activity
may be affected by down-regulation of sFRP-1 in DD.
Importantly, post-translational modification of Wnt/β-
catenin signalling pathway components, such as altered
phosphorylation, acetylation, methylation, ubiquitina-
tion, sumoylation, glycosylation or lipidation, could con-
tribute to an altered responses of DD cells to upstream
signalling molecules. In addition, while we have shownJournal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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that exon 3 mutations of the β-catenin gene are not evi-
dent in DD [8], we have not ruled out the possibility that
changes to other regions of this or other genes encoding
integral components of this pathway such as APC may be
altering the sensitivity of DD cells to Wnt signalling. We
are presently assessing the activity of GSK-3β in DD to
determine if upstream signalling molecules are regulating
kinase activity and cytoplasmic stability of β-catenin in
this fibroproliferative disorder.
Conclusion
Wnt gene expression was shown to be affected by in vitro
culture, both in routine monolayer culture and in three
dimensional culture in FPCL, when assessed by RT-PCR.
Affymetrix Microarray analysis, degenerate primer analy-
sis and Real Time relative PCR quantitation were per-
formed and, with the exception of Wnt 10b where
expression was highly variable between analyses, the data
indicate that overall Wnt expression is unchanged
between samples derived from surgical specimens of DD
and those derived from normal PF. As such, alterations in
the expression levels of individual Wnt subtypes are
unlikely to be contributing to the observed dysregulation
of β-catenin expression in DD.
Methods
Clinical specimen collection
DD patient specimens (normal and disease PF) were col-
lected in compliance with the University's Human
Research Ethics Committee. Disease cords and nodules
(disease) and uninvolved normal fascia (control) were
collected from patients undergoing surgical resection of
DD lesions as following: All samples used in the current
study were from primary resections. In the operating
room, the superficial surface of the affected palmar fascia
including a surrounding area of normal appearing fascia
was widely exposed. The diseased part was subsequently
resected with a cuff of normal appearing palmar fascia. On
the side table, the diseased cord was then removed from
the resected specimen and immediately sent to the lab. In
addition, an area of uninvolved normal appearing fascia
(control) well-away from the resected specimen was har-
vested. To incorporate a "true normal", palmar fascia from
patients who do not have any signs of Dupuytren's disease
was harvested. Thus, one sample from a patient undergo-
ing carpal tunnel release was also utilized in the Affyme-
trix Microarray study. The majority of clinical specimens
were processed immediately for total RNA isolation as
described below, unless otherwise indicated, in which
case samples were stored at -80°C prior to processing.
Affymetrix microarray analysis
Surgical specimens were transferred to dry ice immedi-
ately after clinical dissection. Approximately 100 mg tis-
sue samples were minced into small pieces on dry ice and
then snap-frozen in Liquid Nitrogen. Tissue samples were
ground in a mortar and pestle and 1 ml TRIzol reagent
(Invitrogen Canada Inc., Burlington, Ontario) was added
until all the powder dissolved. Samples were transferred
to 1.5 ml microcentrifuge tubes and total RNA was iso-
lated using TRIzol procedure. Total RNA was purified and
stabilized using RNeasy Minikit (Qiagen Inc., Missis-
sauga, Ontario). Aliquots (3 μl) were screened using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Missis-
sauga, Ontario) and high quality RNA samples were sub-
mitted to the London Regional Genomic Center http://
www.lrgc.ca for Microarray analysis on a Human Genome
U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA). The
data generated represents the expression analysis from all
samples (3 DD compared to 3 control consisting of 2 PF
and 1 carpal tunnel release). The data was analyzed using
Genespring software (Agilent Technologies, Mississauga,
Ontario).
Primary cell monolayer culture
Primary cell cultures were established as previously
described [9,49]. Initially, primary cell cultures were
grown in starter media containing α-MEM (Gibco, Invit-
rogen Corporation), 20% fetal bovine serum (FBS, Clon-
tech Laboratories, Palo Alto, CA), penicillin G +
streptomycin sulfate, and fungizone (Gibco, Invitrogen
Corporation). Established primary cell cultures were
maintained in α-MEM + 10% FBS + antibiotics + fungi-
zone at 37°C in a humidified chamber with 5% CO2.
Fibroblast populated collagen lattice (FPCL) cultures
Collagen lattices were prepared as a modified version of
the method described previously [8]. Briefly, phosphate
buffered solution (PBS) suspensions of primary cell cul-
tures (passages 2 – 6) were mixed with a neutralized solu-
tion of Vitrogen100 (Collagen Corp, Santa Clara, CA,
USA) collagen type I matrix (8 parts Vitrogen100, 2.9 mg/
ml + 1 part 10× α-MEM + 1 part HEPES buffer, pH 9.0).
The cell-collagen concentrations were adjusted with PBS
to attain a final collagen concentration of 2.0 mg/ml and
a final cell concentration of 105 cells/ml of matrix. The
cell-collagen mixture was then dispensed into 24 well cul-
ture dishes (0.5 ml/well) that were pre-treated with a PBS
solution containing 2% (w/v) bovine serum albumin
(BSA). Following FPCL polymerization, 0.5 ml of growth
medium (α-MEM, 10% FBS) was added on top of each lat-
tice. After 4 days of culture the attached FPCLs were har-
vested for RNA extraction using the RNeasy® columns
according to the manufacturer's instructions (Qiagen,
Mississauga, ON, Canada).
Degenerate Wnt primer design
Progressive multiple sequence alignment of the Wnt gene
family was carried out using the ClustalW program with
the aid of the BioEdit sequence alignment editor [41].Journal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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Comparison of the published nucleic acid sequences for
the 13 human Wnts detected by Affymetrix Microarray
revealed several highly conserved regions that were used
to design degenerate oligonucleotide primers for PCR
amplification as previously described [42].
RNA extraction and PCR amplification of Wnt genes using 
degenerate oligonucleotide primers
RNA extraction from tissues was carried out as previously
described. First-strand cDNA was reverse transcribed (RT)
from 1 mg of total RNA using random hexamer priming
and SuperScript™ II reverse transcriptase in a final volume
of 50 ml, as recommended by the manufacturer (Invitro-
gen, Carlsbad, CA, USA). Following first strand synthesis,
cDNA was amplified using the following degenerate oli-
gonucleotide primers:
(UP) upper primer 5'-GGGGAATTCANCGAVTSYAART-
GYCAY-3'
(LP) lower primer 5' – AAAAGATCTGCACCACCAVYG-
SWM-3'
where V = ACG, N = ACGT, R = AG, M = AC, Y = CT, H =
ACT, W = AT, S = CG, K = TG and B=CGT
Standard PCR amplification was performed in a PX2 Ther-
mal Cycler (Thermo Electron Corporation) using 4 μl of
RT cDNA, 1 mM MgCl2, 200 μM of dNTPs (Invitrogen,
Carlsbad, CA, USA), 1 μM of primers, and 1 unit of Plati-
num®  Taq DNA Polymerase (Invitrogen, Carlsbad,
CA,.USA) in Taq PCR buffer (10 mM Tris pH8.3, 50 mM
KCl). PCR cycling parameters were 94°C for 5 min, fol-
lowed by 40 cycles of 94°C for 1 min., 59°C for 1.5 min.,
72°C for 2 min., followed by a final extension at 72°C of
10 min.
Cloning of PCR products and screening of transformants
PCR products (~400 bp) were directly subcloned into the
pCR® 4-TOPO® sequencing vector using a TOPO TA clon-
ing kit, as recommended by the manufacturer (Invitro-
gen). Ligation products were then used to transform
TOP10 chemically competent E. coli cells, and transform-
ants selected for using standard ampicillin (100 μg/ml)
supplemented LB agar plates. Plasmid DNA was purified
from selected colonies using Qiagen mini-prep columns
(Qiagen, Mississauga, ON, Canada). Plasmid DNA was
quantified by spectrophotometry (OD260), digested with
EcoRI (pCR4-TOPO subcloned amplicons are flanked by
EcoRI sites), and subjected to 2% agarose gel electrophore-
sis. DNA bands were gel purified (Qiagen gel extraction
kit) and then digested with a series of diagnostic restric-
tion endonuclease (RE), including Eco RI, Eco RII and Sac
II. DNA fragments were then size-separated using native
(non-denaturing) acrylamide (12%) gel electrophoresis.
Gels were stained with ethidium bromide, placed on a UV
transilluminator (FisherBiotech) and photographed using
Polaroid film (type 667) and a Polaroid DS-34 camera fit-
ted with a UV filter (Polaroid, UK). The DNA fragmenta-
tion patterns were analyzed (i.e. RE grouping), and several
clones from each RE group were sequenced to confirm
their Wnt identity.
RT-PCR using Wnt-specific primers
Briefly, 200 ng of total RNA from tissue or cells were
reverse transcribed using random hexamers and Super-
Script™ II RT as described above (Invitrogen, Carlsbad,
CA, USA). Following first strand synthesis, Wnt specific
PCR amplifications were carried out using 1 μl of cDNA,
1.5 mM MgCl2, 200 μM of dNTP mix (Invitrogen,
Carlsbad, CA, USA), 0.8 μM of primers (see below), and
0.75 units of Platinum® Taq DNA Polymerase (Invitrogen,
Carlsbad, CA., USA) in Taq PCR buffer (10 mM Tris
pH8.3, 50 mM KCl), in a final reaction volume of 25 μl.
Sequences of the Wnt-specific primer were as following:
Wnt5a upper primer (Wnt5a-UP): 5' – aagaagtgcacgga-
gatcgt – 3'
Wnt5a lower primer (Wnt5a-LP): 5' – tggaacctacccatcccata
– 3'
Wnt9a upper primer (Wnt9a-UP): 5' – gcaagcatctgaag-
cacaag – 3'
Wnt9a lower primer (Wnt9a-LP): 5' – tgctctcgcagttcttctca
– 3'
Wnt10b upper primer (Wnt10b-UP): 5' – ctggtgctgctatgt-
gctgt – 3'
Wnt10b lower primer (Wnt10b-LP): 5' – cccagccaaaaggag-
tatga – 3'
Wnt11 upper primer (Wnt11-UP): 5' – tgacctcaagacccga-
tacc – 3'
Wnt11 lower primer (Wnt11-LP): 5' – tgagggtccttgagca-
gagt – 3'
GAPDH upper primer: 5' – gtcagtggtggacctgacct – 3'
GAPDH lower primer: 5' – aggggtctacatggcaactg – 3'
PCR cycling parameters were optimized for Wnt5a,
Wnt9a, Wnt10b, Wnt11 and GAPDH to ensure log linear
amplification of these products. For Wnt5a, Wnt9a,
Wnt10b, Wnt11 were 94°C for 3 min, followed by 32
cycles of 94°C for 30 sec., 62°C for 45 sec., 72°C for 45
sec., followed by a final extension at 72°C of 7 min. PCRJournal of Negative Results in BioMedicine 2006, 5:13 http://www.jnrbm.com/content/5/1/13
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conditions for GAPDH were the same as above except 25
cycles were used. PCR samples were then subjected to 2%
agarose gel electrophoresis, with the resulting amplicons
being visualized by ethidium bromide staining. Digital
images of the gels were captured and analyzed using a gel
documentation workstation (Alpha Innotech Corp., San
Leandro, CA, USA).
Real Time PCR
Real time PCR was performed on an ABI Prism 7700
(Applied Biosystems, Foster City, CA. USA) using the rel-
ative quantitation, or "comparative Ct" method. In brief,
TRIzol reagent (Invitrogen) and RNeasy® Mini Kits (Qia-
gen, Mississauga, ON) were used to isolate total RNA from
surgically resected normal and diseased tissue from
patients with Dupuytren's Contracture. RNA quality was
determined on an Agilent 2100 Bioanalyzer and only
samples with minimal degradation were used for analysis.
10 μg of total RNA was reverse transcribed into cDNA first
strand using the High-Capacity cDNA Archive Kit
(Applied Biosystems) in accordance with the manufac-
turer's instructions. For validity, the comparative Ct
method requires that the amplification efficiency of the
target and endogenous control transcripts be equivalent.
To assess this, dilutions of cDNA first strand correspond-
ing to 1000 ng, 500 ng, 100 ng, 50 ng, 10 ng and 0 ng were
introduced into the PCR reactions. Coupled with the tar-
get genes Wnt 10b and Wnt 11, endogenous control gene
products were amplified by gene specific probe sets con-
taining TaqMan®  MGB probes labelled with 6-FAM™
(Applied Biosystems, Wnt 10b Assay Id Hs00559664_m1;
Wnt 11 Assay ID Hs00182986_m1). Triplicate reactions
of each dilution were performed (50 μl samples) in a 96-
well plate format using SDS instrumentation (Applied
Biosystems) for 45 cycles. Target and endogenous control
reaction were run in separate wells in triplicate at each
concentration. To determine if the target and endogenous
control gene products amplified with the same efficiency,
the  Δ C T value (CT target/CT endogenous control) was plotted
against the log input cDNA to create a semi-log regression
line. A "pass" value of <0.2 for the slope of Δ CT vs. log
input was used in this study. β-actin amplification passed
validation with Δ CT vs. log input values of 0.1696 and
0.1619 for Wnt 10b and Wnt 11 respectively, and this con-
trol was subsequently used for all real time relative quan-
titation in this study.
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